» Articles » PMID: 17344572

Inhaled Insulins

Overview
Journal Postgrad Med J
Specialty General Medicine
Date 2007 Mar 9
PMID 17344572
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

As a result of knowledge gained from the management of asthma with inhalers and nebulisers, pulmonary delivery devices for insulin have been developed. Particle size of the aerosol particularly influences drug delivery. Although several pharmaceutical companies are developing different systems, Pfizer have launched the first inhaled insulin (Exubera). Clinical trials have taken place in patients with both type 1 and type 2 diabetes, but have shown similar glucose control as subcutaneous insulin delivery. However, patient satisfaction does seem to be increased in patients taking inhaled insulins. Further studies are needed to investigate compliance, side-effect profiles, quality of life, long-term glycaemia control and cost effectiveness.

Citing Articles

The Discovery of Insulin: An Important Milestone in the History of Medicine.

Vecchio I, Tornali C, Bragazzi N, Martini M Front Endocrinol (Lausanne). 2018; 9:613.

PMID: 30405529 PMC: 6205949. DOI: 10.3389/fendo.2018.00613.


Technosphere insulin: defining the role of Technosphere particles at the cellular level.

Angelo R, Rousseau K, Grant M, Leone-Bay A, Richardson P J Diabetes Sci Technol. 2010; 3(3):545-54.

PMID: 20144294 PMC: 2769873. DOI: 10.1177/193229680900300320.


Pharmaceutical particle engineering via spray drying.

Vehring R Pharm Res. 2007; 25(5):999-1022.

PMID: 18040761 PMC: 2292490. DOI: 10.1007/s11095-007-9475-1.

References
1.
Rosenstock J, Zinman B, Murphy L, Clement S, Moore P, Bowering C . Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2005; 143(8):549-58. DOI: 10.7326/0003-4819-143-8-200510180-00005. View

2.
Heinemann L, Traut T, Heise T . Time-action profile of inhaled insulin. Diabet Med. 1997; 14(1):63-72. DOI: 10.1002/(SICI)1096-9136(199701)14:1<63::AID-DIA298>3.0.CO;2-F. View

3.
Cappelleri J, Cefalu W, Rosenstock J, Kourides I, Gerber R . Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. Clin Ther. 2002; 24(4):552-64. DOI: 10.1016/s0149-2918(02)85131-1. View

4.
Heise T, Bott S, Tusek C, Stephan J, Kawabata T, Finco-Kent D . The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic study. Diabetes Care. 2005; 28(9):2161-9. DOI: 10.2337/diacare.28.9.2161. View

5.
Cefalu W . Evolving strategies for insulin delivery and therapy. Drugs. 2004; 64(11):1149-61. DOI: 10.2165/00003495-200464110-00001. View